Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Reduce" from Analysts

Key Points

• Analysts have given Hims & Hers Health, Inc. an average recommendation of "Reduce," with ratings from 13 analysts indicating three sell recommendations, eight hold recommendations, and two buy recommendations.
• The company reported a 72.6% increase in revenue year-over-year but fell short of analysts' consensus EPS estimates, posting $0.17 instead of the expected $0.18.
• Insider trading activity includes CEO Andrew Dudum selling 660,000 shares for over $33 million, marking a 22.96% decrease in his position.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given a consensus rating of "Reduce" by the thirteen analysts that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $38.9167.

Several research firms have commented on HIMS. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price objective for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Finally, Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $44.53 on Friday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business has a 50-day moving average of $51.71 and a two-hundred day moving average of $45.78. The stock has a market capitalization of $10.06 billion, a P/E ratio of 55.66, a P/E/G ratio of 2.97 and a beta of 2.08. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the sale, the chief executive officer owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 23,107 shares of the stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at approximately $2,987,239.50. This trade represents a 26.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,396,090 shares of company stock worth $71,927,627 over the last three months. 13.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. lifted its stake in Hims & Hers Health by 139.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after buying an additional 45,791 shares in the last quarter. Mariner LLC boosted its stake in Hims & Hers Health by 77.4% during the fourth quarter. Mariner LLC now owns 19,943 shares of the company's stock worth $482,000 after buying an additional 8,699 shares during the period. Guggenheim Capital LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at $274,000. NewEdge Advisors LLC increased its stake in Hims & Hers Health by 83.4% in the 4th quarter. NewEdge Advisors LLC now owns 20,021 shares of the company's stock valued at $484,000 after buying an additional 9,105 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Hims & Hers Health by 46.5% in the 4th quarter. First Trust Advisors LP now owns 355,103 shares of the company's stock worth $8,586,000 after buying an additional 112,772 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.